Hydroxychloroquine and Covid-19: The never-ending story

The novel Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), also known as COVID-19, has caused a pandemic that has rapidly spread across the world and has caused great public health concer.

RESULTS: A total of 09 published articles were identified: 03 clinical trials with a sample size of 150; 03 in vitro studies and 03 expert consensus repor.

Hydroxychloroquine and Chloroquine SARS-CoV-2 (COVID-19) Clinical Studies:

Conclusion: Both chloroquine and hydroxychloroquine have antiviral properties in vit.

What happened next, however, was an unfortunate comedy of errors, wasting resources and opportunities to find an effective cu.

Hundreds of clinical trials were launched in spring 2020 to evaluate whether hydroxychloroquine can prevent or treat COVID-1 Based on publicly available data, 247 such trials were register.

With dozens of trials published, hydroxychloroquine is finally shut down for COVID-1 But it would be remiss not to draw some lessons for future epidemics and general clinical scien.

Don’t put the cart before the horse

While slow and arduous, the gradual progression of candidate therapies from in vitro effects to animal models to expanding clinical trials is critical to avoid mis-prioritization of drugs that have little prospect of success but risk diverting scarce resources and exposing patients to potential ha.

There is no “me” in the team

Although large clinical trial platforms such as RECOVERY and REMAP-CAP have made significant strides in hospitalization of COVID-19 patients from the outset, the lack of large-scale, coordinated efforts to minimize duplication and accelerate results10 An early outpatient study was hinder.

Ultimately, hydroxychloroquine has no clinical benefit against COVID-1 The efforts of trial staff and the goodwill of patients who volunteered to study should not be undermined, but the lessons learned from this fiasco must inspire us to do better in the next pandem.

references:

Meo SA, Klonoff DC, Akram.